Skip to content

Study · Observational study · n = 2,374 · 2017

4 results

A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapies.

Wei W, Buysman E, Grabner M, Xie L, Brekke L, Ke X, Chu JW, Levin PA

Diabetes, obesity & metabolism20 Jan 2017Cited by 22 (Europe PMC)

PMID27860158 (opens in a new tab)PMCIDPMC5347924 (opens in a new tab)DOI10.1111/dom.12828 (opens in a new tab)PepBankPUB-27860158
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In US adults with type 2 diabetes starting liraglutide, mean HbA1c fell by 0.51% over 12 months of follow-up.

    In plain wordsIn US adults with type 2 diabetes who started liraglutide, average HbA1c fell by 0.51% over 12 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change at 12 months
    Study

    n = 2,374

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 months of follow-upAs given in this study (human).

    Measurements

    Mean HbA1c change
    −0.51%
    liraglutide

    Source sentences

    Summary
    During 12-months of follow-up, treatment persistence was 64%, mean HbA1c reduction was -1.24% and weight change was + 1.17 among GLA patients, and was 49%, -0.51% and -2.74 kg, respectively, among LIRA patients.
    2 context sentences
    Summary · context
    Linked insurance claims and medical record data were collected from 2 large US health insurers (April 1, 2010 to March 31, 2012) of T2DM adults initiating treatment with glargine (GLA) or liraglutide (LIRA).
    Summary · context
    A total of 4490 patients were included (GLA, 2116; LIRA, 2374).
  2. 02HumanObservational studyEfficacy outcome

    In US adults with type 2 diabetes starting liraglutide, weight fell by 2.74 kg over 12 months of follow-up.

    In plain wordsIn US adults with type 2 diabetes who started liraglutide, weight fell by 2.74 kg over 12 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight change at 12 months
    Study

    n = 2,374

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 months of follow-upAs given in this study (human).

    Measurements

    Weight change
    −2.74 kg
    liraglutide

    Source sentences

    Summary
    During 12-months of follow-up, treatment persistence was 64%, mean HbA1c reduction was -1.24% and weight change was + 1.17 among GLA patients, and was 49%, -0.51% and -2.74 kg, respectively, among LIRA patients.
    2 context sentences
    Summary · context
    Linked insurance claims and medical record data were collected from 2 large US health insurers (April 1, 2010 to March 31, 2012) of T2DM adults initiating treatment with glargine (GLA) or liraglutide (LIRA).
    Summary · context
    A total of 4490 patients were included (GLA, 2116; LIRA, 2374).
  3. 03HumanObservational studyOther

    In US adults with type 2 diabetes starting liraglutide, treatment persistence over 12 months was 49%.

    In plain wordsIn US adults with type 2 diabetes who started liraglutide, 49% were still on treatment after 12 months.

    Peptide
    Liraglutide
    Outcome
    Not applicableTreatment persistence at 12 months
    Study

    n = 2,374

    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated · 12 months of follow-upAs given in this study (human).

    Measurements

    Treatment persistence
    49%
    liraglutide

    Source sentences

    Summary
    During 12-months of follow-up, treatment persistence was 64%, mean HbA1c reduction was -1.24% and weight change was + 1.17 among GLA patients, and was 49%, -0.51% and -2.74 kg, respectively, among LIRA patients.
    2 context sentences
    Summary · context
    Linked insurance claims and medical record data were collected from 2 large US health insurers (April 1, 2010 to March 31, 2012) of T2DM adults initiating treatment with glargine (GLA) or liraglutide (LIRA).
    Summary · context
    A total of 4490 patients were included (GLA, 2116; LIRA, 2374).
  4. 04HumanObservational studyOther

    In US adults with type 2 diabetes starting liraglutide, diabetes-related costs rose significantly from baseline to follow-up.

    In plain wordsIn US adults with type 2 diabetes who started liraglutide, diabetes-related costs were higher after 12 months than before.

    Peptide
    Liraglutide
    Outcome
    IncreaseDiabetes-related costs
    Study

    n = 2,374

    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated · 12 months of follow-upAs given in this study (human).

    Measurements

    Diabetes-related costs
    2089 USD
    baseline
    Diabetes-related costs
    3258 USD
    follow-up

    Source sentences

    Summary
    Diabetes-related costs increased significantly from baseline to follow-up for LIRA patients ($2089 vs $3258, P < .001) but not for GLA patients ($3492 vs $3550, P = .890).
    2 context sentences
    Summary · context
    Linked insurance claims and medical record data were collected from 2 large US health insurers (April 1, 2010 to March 31, 2012) of T2DM adults initiating treatment with glargine (GLA) or liraglutide (LIRA).
    Summary · context
    A total of 4490 patients were included (GLA, 2116; LIRA, 2374).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.